Panacea Announces Phase I Clinical Preliminary Results of the World's First Prostate Cancer Nanoparticle Vaccine February 05, 2018 Source: Sina Pharmaceutical Recently, Panacea Pharmaceuticals, a US biopharmaceutical company dedicated to developing innovative therapeutic therapies and diagnostic methods for the cancer field, announced that it has completed the recruitment of clinical phase 1 trial patients for vaccine PAN-301-1 for continuous prostate cancer treatment. The trial was used to assess the safety and immunogenicity of PAN-301-1 treatment and was an open-label, parallel-design, multicenter study. PAN-301-1 is a novel nanoparticle targeting human aspartyl (asparaginyl) beta-hydroxylase (HAAH), also known as aspartate beta-hydroxylase (ASPH). Immunotherapeutic vaccine. In this clinical phase 1 trial, PAN-301-1 was treated by intradermal injection for biochemically relapsed prostate cancer patients. The recommended doses for subsequent clinical phase 2 trials were obtained using a fixed dose escalation every 21 days. A total of 12 patients were enrolled in the study, and each subject received at least 3 doses of vaccine. After the recruitment of this patient, the study will end in the first half of 2018. The current preliminary safety and immunogen data points are as follows: 1. PAN-301-1 therapeutic vaccine is well tolerated and safe in clinical phase 1 studies. 2. No drug-related adverse events or dose-limiting toxicity were observed at the three vaccine dose levels. 3. All subjects experienced a dose-dependent HAAH-specific immune response, including antibody levels in immunoassays, B cell and T cell responses. 4. Most subjects who received treatment for more than 3 months received a significant reduction in prostate specific antigen (PSA) (a measure of disease progression) and will be decided by the investigator to continue accepting PAN-301-1 Administration. Dr. Hossein A. Ghanbari, President, CEO and Chief Scientific Officer of Panacea Pharmaceuticals, said: "We are very pleased with the rapid progress of Phase 1 clinical trials. The results suggest that we have created a target that targets specific tumors and overcomes them. A safe and promising new therapeutic cancer vaccine that is self-tolerant, while avoiding the serious side effects associated with many other cancer immunotherapeutics. It is expected to publish more detailed results of this study at this year's medical conference." Dr. Steven A. Fuller, Chief Operating Officer of the company, said: "Twelve subjects have been injected with more than 90 doses of this vaccine. This vaccine is well tolerated in patients. Based on these results, we are planning to be under 2018. Phase II clinical trials began in half a year." PAN-301-1 is a novel immunostimulatory nanoparticle vaccine preparation with hundreds of copies of HAAH fragments on the surface of the nanoparticles. HAAH is usually an enzyme expressed during fetal development that plays an important role in cell growth, movement, and cell-to-cell interactions. At birth, the gene is silent. HAAH is up-regulated in tumor cells and is associated with tumor cell growth, cell movement and invasion. HAAH is expressed only on the surface of cancer cells and is detected in more than 20 different types of cancer. The expression level of HAAH was negatively correlated with the prognosis of the disease. When normal cells transfect the HAAH gene, they behave like cancer cells, and when HAAH is inhibited in cancer cells, they behave like normal cells. PAN-301-1 is designed to overcome autologous tolerance by altering antigen presentation and providing immune stimulation. The nanoparticles can neutralize phage, are easy to industrialize and are convenient for administration to patients. The nanoparticle vaccine also contains DNA fragments that exhibit a phage CPG motif that activates the MHC class II pathway. The vaccine was administered intradermally by the use of 3M reservoir type microstructural transdermal drug delivery technology (hMTS). The use of hMTS results in a small, fast and almost painless injection process that saves time and eliminates the uncomfortable feeling of ordinary injections, greatly facilitating ease of use and patient acceptance. (Sina Pharmaceutical Compilation / David) Article Reference Source: Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-in-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer
â… Product Composition: polydadmac
â…¡ Product Properties
The appearance of this product is colorless to pale yellow viscous liquid. It is soluble in water. It has goodhydrolyticstability and high adaptability to PH value changes. It`s safe and non-toxic. Its freezing point is about -2.8℃, specific gravity is about 1.04/cm3 and decomposition temperature is 280-300℃. It`s polymeride AKD maturing agent of high charge density. Emulsion provides strong cationic component promotive and protective agent and promotes curing effect. This product is added directly into the synthesis process of intermediates or added a certain ratio in emulsion. This product can be added more in the papermaking system with heavier anionic trash, as the pulp potential equilibrium to play a dual role of sizing enhancement and forcing ripening.
III. Quality indicators;
Appearance: colorless to faint yellow thick liquid Solid content: 40±1%
PH value: 4.0~7.0 viscosity (mpa.s, 25℃): 7000-12000
IV. Application:
This product is applied in alkaline sizing system of AKD (Alkyl Ketene Dimer) to restrict largely the hydrolysis and migration aptitude of AKD. [The third generation" AKD is mainly used for the making of multipurpose duplicating paper filled by precipitated calcium carbonate. 60% cationic polymer can adhere to the fiber after the paper containing cationic polymer being reused, by which enhance hydrophobicity of the paper. Added to waste paper deinking agent, its cationic hydrophilic group adheres to ink particles easily, especially for hydrophobic aniline ink. After flotation, the whiteness of pulp increased. This product is also applied as cationic surfactant in pitch control agent for pulping.
Curing Agent,Poly Dadmac,Paper Curing Agent,Adhesive Curing Agent Shandong Tiancheng Chemical Co., Ltd. , https://www.tianchengchemical.com
